Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

GC-MS chromatogram of garlic essential oil. حسب Huda H. Elbehery (22492996)

Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. حسب Joanna Gutral (12101779)

Distribution of mean seasonal rainfall in the study area. حسب Menbere Sahilu (18195856)

الموضوعات:

Distribution of mean monthly rainfall in the study area. حسب Menbere Sahilu (18195856)

الموضوعات:

Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone. حسب Brenda Lyn A. Gavina (15285185)

Descriptive statistics of data presented in Tables 2–5. حسب Héctor Raúl Olivares-Sánchez (13014866)

RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. حسب Xiaojuan Li (351842)

Chemokines, with the exception of CXCL1 and MCP-1, decrease acutely following 5 Gy IR. حسب Jordan A. Gunning (18143970)

Fig 5 - حسب Harshita Sharma (4836180)

Descriptive statistics (mean [standard deviation] or % [sample size]) for study variables analyzed in the current study. حسب Angelina R. Sutin (9216456)